Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IRGPG
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ADC3-9
|
|||||
| Synonyms |
ADC3 9
Click to Show/Hide
|
|||||
| Organization |
BeiGene Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Colorectal cancer [ICD11:2B91]
Investigative
Non-small cell lung cancer [ICD11:2C25]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
7.9
|
|||||
| Structure |
|
|||||
| Antibody Name |
Patritumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-3 (ERBB3)
|
Antigen Info | ||||
| Payload Name |
ADC 3-9 payload
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
ADC 3-9 linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) | 65.10% | Positive HER2 expression (HER2 +++/++) | ||
| Method Description |
Seeding cells (HCC1569) into 96-well plate, at 2E3 cell per well (80 uL/well). Overnight incubation.
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1569 cells | CVCL_1255 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 3.18 nM | Positive HER2 expression (HER2 +++/++) | ||
| Method Description |
Seeding cells (HCC1569) into 96-well plate, at 2E3 cell per well (80 uL/well). Overnight incubation.
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1569 cells | CVCL_1255 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.